This paper is only available as a PDF. To read, Please Download here.
Abstract
A group of women treated with six levonorgestrel covered rods participated in a study
on general chemistry and blood levels of selected hormones at treatment months 20
and 65. A comparable group of Copper T users served as control. Parameters analyzed
were the SMA 12 chemistry profile, estradiol, testosterone, cortisol, T3, T4 and TSH. Samples from treated and control subjects were drawn within the same calendar
period and were run simultaneously for the assay of each parameter.
The values observed were within the normal limits. Significantly higher values of
total protein and albumin and lower levels of estradiol and testosterone were found
among implant users when compared to the control group. The results suggests little
or no metabolic changes in users of six levonorgestrel covered rods which release
a daily dose of approximately 105 micrograms.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to ContraceptionAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- First year clinical experience with six levonorgestrel rods as subdermal contraception.Contraception. 1979; 20: 167-175
Robertson, D.N., Diaz, S., Alvarez-Sanchez, F., Holma, P., Mishell, D.R., Coutinho, E., Brache, V., Croxatto, H.B., Faundes, F., Lacarra, M., Pavez, M., Roy, S., da Silva, A.R., Sivin, I., and Stern, J. Contraception with Long-Acting Subdermal Implants. A Five-Year Clinical Trial with Silastic Covered Rod Implants Containing Levonorgestrel. In press.
- Release rates of levonorgestrel from Silastic capsules, homogenous rods and covered rods in humans.Contraception. 1983; 27: 483-495
- Clinical chemistry in women treated with levonorgestrel implants (Norplant™)or a TCu 200 IUD.Contraception. 1983; 27: 281-288
- Contraception with long-acting subdermal implants. I. An effective and acceptable modality in international clinical trial.Contraception. 1978; 18: 315-333
- Contraception with long-acting subdermal implants: II. Measured and perceived effects in international clinical trial.Contraception. 1978; 18: 335-353
- The influence of hormonal contraceptives on sex hormone binding globulin (SHBG) capacity.Contraception. 1975; 11: 53-59
- Sex hormone binding globulin: the carrier protein for d-norgestrel.J Clin Endocrinol Metab. 1976; 43: 244-247
- Subdermal levonorgestrel implants: Serum androgens.Contracept Deliv Syst. 1983; 4: 127-131
Olsson, S-E., Odlind, V., Johansson, E.D.B. Androgen levels in women using NorplantR implants. Contraception, submitted.
Article info
Publication history
Accepted:
March 15,
1985
Received:
February 21,
1985
Identification
Copyright
© 1985 Published by Elsevier Inc.
